Contact

Our portfolio

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

  • Institute: Amsterdam UMC
Industry: Infectious Disease, Oncology, Therapeutics
  • Founding year: 2021
Visit website

Want to get in contact about Kling Biotherapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Oefenweb.nl
Developing adaptive online learning systems.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
AMI Pharma
Advancing new therapeutics for Type 1 Diabetes and autoimmune diseases.
Oefenweb.nl
Developing adaptive online learning systems.
Explore full AAV portfolio
Contact